Corrigendum to “A Single-Centre Study on the Impact of Co-Mutations on Osimertinib Efficacy in EGFR-Mutated NSCLC” [Lung Cancer 200(Supplement 1) (February 2025) 108218]

IF 4.4 2区医学 Q1 ONCOLOGY

Lung Cancer Pub Date : 2025-07-01 DOI:10.1016/j.lungcan.2025.108582

Bethany Wyatt, Lilian Cheung, Joss Adams, Shawn Ellis

引用次数: 0

查看原文本刊更多论文

“一项关于共突变对奥西替尼治疗egfr突变NSCLC疗效影响的单中心研究”的更正[肺癌200（增刊1）（2025年2月）108218]

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lung Cancer 医学-呼吸系统

CiteScore

9.40

自引率

3.80%

发文量

407

审稿时长

25 days

期刊介绍： Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.